Unions that provide health benefits to nearly a half-million workers — including many in Ohio — have filed nearly identical ...

City attorneys allege major Pharmacy Benefit Managers (PBMs) and insulin manufacturers are conspiring to artificially inflate ...

Birmingham is suing drug manufacturers and health companies, alleging they worked together to establish an “insulin pricing scheme” and inflate the cost of life-saving medicine.

Novo Nordisk, alongside American competitor Eli Lilly (LLY), dominates the global insulin market, focusing on diabetes care.

Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

Founded a century ago, Copenhagen-based Nordisk originally made insulin. After coming to the US in 1982, it underwent several corporate changes until becoming Novo Nordisk in 1989. In addition to ...

UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s ...

In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price ...

According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.